EP1680402A1 - Derives de n-[[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique - Google Patents

Derives de n-[[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique

Info

Publication number
EP1680402A1
EP1680402A1 EP04791551A EP04791551A EP1680402A1 EP 1680402 A1 EP1680402 A1 EP 1680402A1 EP 04791551 A EP04791551 A EP 04791551A EP 04791551 A EP04791551 A EP 04791551A EP 1680402 A1 EP1680402 A1 EP 1680402A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
group
general formula
disorders
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04791551A
Other languages
German (de)
English (en)
French (fr)
Inventor
Gihad Dargazanli
Geneviève ESTENNE-BOUHTOU
Pascale Magat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of EP1680402A1 publication Critical patent/EP1680402A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • Ri represents either a hydrogen atom, or a linear or branched (C ⁇ -C) alkyl group optionally substituted by one or more fluorine atoms, or a (CC 7 ) cycloalkyl group, or a (C3-C7) cycloalkyl- group (C 1 -C3) alkyl, either a phenyl group (C ⁇ ⁇ C 3 ) alkyl optionally substituted by one or two methoxy groups, or a (C 2 -C 4 ) alkenyl group, or a (C 2 -C) alkynyl group ,
  • X represents a hydrogen atom or one or more substituents chosen from halogen atoms and trifluoromethyl groups, (C 1 -C 4 ) alkyl and (C 1 -C 4 ) linear or branched alkoxy
  • R 2 represents a group selected from the groups naphthalenyl, pyridinyl, pyri idinyl, pyrazinyl, pyridazinyl, triazinyl, indanyl, indenyl, quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, thienyl, furyl, pyrrolyl, imidazolyl, pyidolol, pyolazolyl, pyrazolyl thiadiazolyl, oxadiazolyl, triazolyl, benzothienyl, benzofuryl, benzimidazolyl, benzothi
  • the compounds of general formula (I) can exist in the form of the threo racemate ⁇ 1R, 2R; 1.5.2S) or in the form of (1R, 2R) or (1S, 2S) enantiomers; they can exist in the form of free bases or of addition salts with acids.
  • the preferred compounds of the invention lack activity on opiate receptors or 5-HT3 and exhibit particular activity as specific inhibitors of the glycine transporters glytl and / or glyt2.
  • a diamine of general formula is coupled (II), in which Ri and X are as defined above (with Ri different from a hydrogen atom) with an activated acid or an acid chloride of general formula (III) in which Y represents a group OH activated or a
  • chlorine atom and R 2 is as defined above, using the methods known to those skilled in the art.
  • the diamine of general formula (II) can be prepared by a process illustrated by scheme 2 which follows.
  • the Weinreb amide of formula (IV) is reacted with the phenyllithium derivative of general formula (V), in which X is as defined above, in an ethereal solvent such as diethyl ether, between -30 ° C and room temperature; a ketone of general formula (VI) is obtained which is reduced to alcohol of threo configuration of general formula (VII) by a reducing agent such as K-Selectride® or L-Selectride® (tri-sec-butyl- potassium or lithium borohydride), in an ethereal solvent such as tetrahydrofuran, between -78 ° C and room temperature.
  • the carbamate of general formula (VII) can then be reduced to N-methylaminoalcohol threo of general formula (VIII) by the action of a mixed hydride such as lithium aluminum hydride, in a
  • n ⁇ éthanesulfonate by the action of methylsulfonyl chloride, in a chlorinated solvent such as dichloromethane, and in the presence of a base such as triethylamine, between 0 ° C and room temperature, then reacting the nucleofuge group with ammonia liquefied at -50 ° C, in an alcohol such as ethanol, in a closed environment such as an autoclave, between -50 ° C and room temperature.
  • the diamine of general formula (II) is obtained in which R 1 represents a methyl group and X represents a hydrogen atom in the form of a mixture of the two threo / erythro 9/1 diastereoisomers. It can be salified, for example with oxalic acid, then purified by recrystallization of the oxalate formed in a mixture of alcohol and an ethereal solvent such as methanol and diethyl ether, to obtain the diastereoisomer threo (1R, 2R; 1S, 2S) pure.
  • the compounds of general formula (II) in which R 1 represents a hydrogen atom can be prepared according to scheme 2, with the use of a compound of general formula (I) in which R 1 represents an optionally substituted phenylmethyl group, then deprotection of the nitrogen of the piperidine ring, for example by an oxidizing agent or by a Lewis acid, such as boron tribromide, or by hydrogenolysis, either an alkenyl group, preferably allyl, and deprotecting the nitrogen by a complex of the Pd °, to obtain a compound of general formula (I) in which Ri represents a hydrogen atom.
  • the chiral compounds of general formula (I) corresponding to the (1R, 2R) or (1S, 2S) enantiomers of the threo diastereoisomer can also be obtained by separation of the racemic compounds by high performance liquid chromatography (HPLC) on a chiral column, or by splitting the racemic amine of general formula (II) by using a chiral acid such as tartaric acid, camphorsulfonic acid, dibenzoyltartaric acid or N-acetylleucine, by fractional and preferential recrystallization d 'a diastereoisomeric salt, in an alcohol type solvent, or by enantioselective synthesis according to scheme 2 with the use of a chiral einreb amide of formula (IV).
  • HPLC high performance liquid chromatography
  • the Weinreb amide of formula (IV) racemic or chiral, as well as the ketone of general formula (VI), can be prepared according to a method analogous to that described in Eur. J. Med. Chem. , 35, (2000), 979-988 and J. Med. Chem. , 41, (1998), 591-601.
  • the phenyllithium compound of general formula (V) where X represents a hydrogen atom is commercially available. Its substituted derivatives can be prepared according to a method analogous to that described in Tetrahedron Lett. , 57, 33, (1996), 5905-5908.
  • the pyridineoxime of general formula (XI) can be prepared according to a method analogous to that described in patent application EP-0366006.
  • the amine of general formula (IX) in which X represents a hydrogen atom can be prepared in chiral series according to a method described in patent US-2928835.
  • the amine of general formula (XIII) can be prepared according to a method analogous to that described in Chem. Pharm. Bull. , 32, 12, (1984), 4893-4906 and Synthesis, (1976), 593-595.
  • the acids and acid chlorides of general formula (III) are commercially available, except for 4- [2-chloro-3- (trifluoromethyl) phenyl] -1H-imidazole-2-carboxylic acid, which can be prepared under conditions comparable to those described in patent application EP-0365030 and in patent US-3336300.
  • the precipitate formed is collected by filtration and dried under reduced pressure.
  • Threo (1-methylpiperidin-2-yl) - phenylmethanamine ethanedioate 2 1.
  • 14.8 g (31.89 mmol) of 2- (benzyloxyiminophenylmethyl) -1-methylpyridinium trifluoromethanesulfonate and 0.74 g of platinum oxide are placed in 50 ml of ethanol and 50 ml hydrochloric acid IN and hydrogenation is carried out for 5 h.
  • the ethanol is evaporated off under reduced pressure, the residue is extracted with dichloromethane, the aqueous phase is separated, an ammonia solution is added thereto and it is extracted with dichloromethane.
  • Threo-2,5-dichloro-W- [(1-methyl-2-piperidinyl) (phenyl) methyl] thiophene-3-carboxamide hydrochloride 1 1. 0.768 g (4 mmol) of 2, 5-dichlorothiophene-3-carboxylic acid dissolved in 15 ml of dichloromethane are introduced into a 100 ml flask, then 0.651 ml (4.7 mmol) of triethylamine and 0.447 are successively added ml (4.7 mmol) of ethyl chloroformate, and the reaction mixture is stirred at room temperature for 2 h.
  • threo- (1-methyl-piperidin-2-yl) phenylmethanamine prepared according to example 1.2
  • the mixture is treated with water, it is extracted several times with dichloromethane, the organic phases are washed with water and then with an IN aqueous solution of sodium hydroxide, then with a saturated aqueous solution of sodium chloride, they are dried over sodium and the solvent is evaporated off under reduced pressure, the residue is purified by chromatography on a column of silica gel eluted nt with a mixture of dichloromethane and methanol.
  • N - denotes a compound in the basic state and
  • HC1 denotes a hydrochloride.
  • the compounds of the invention have been subjected to a series of pharmacological tests which have demonstrated their advantage as substances with therapeutic activities.
  • glycine transport in SK-N-MC cells expressing the native glytl human transporter The uptake of [ 14 C] glycine is studied in SK-N-MC cells (human neuroepithelial cells) expressing the native glytl human transporter by measuring the radioactivity incorporated in the presence or absence of the test compound.
  • the cells are cultured in a monolayer for 48 h in plates pretreated with 0.02% fibronectin. On the day of the experiment, the culture medium is eliminated and the cells are washed with a Krebs-HEPES buffer ([4- (2-hydroxyethyl) piperazine-1-ethanesulfonic acid) at pH 7.4.
  • Krebs-HEPES buffer [4- (2-hydroxyethyl) piperazine-1-ethanesulfonic acid
  • the efficacy of the compound is determined by the IC 5 o, the concentration of compound which reduces by 50% the specific capture of glycine, defined by the difference in radioactivity incorporated by the control batch and the batch which received the glycine at 10 mM.
  • the compounds of the invention, in this test, have an IC 50 of the order of 0.01 to 10 ⁇ M. Study of glycine transport in the mouse spinal cord homogenate.
  • the uptake of [ 14 C] glycine by the glyt2 transporter is studied in the mouse spinal cord homogenate by measuring the radioactivity incorporated in the presence or absence of the compound to be studied.
  • the reaction is stopped by vacuum filtration and the radioactivity is estimated by solid scintillation by counting on a Microbeta Tri-lux TM counter.
  • the effectiveness of the compound is determined by the IC 50 concentration capable of decreasing the specific glycine uptake by 50%, defined by the difference in radioactivity incorporated by the control batch and the batch which received the 10 mM glycine.
  • the compounds of the invention, in this test have an IC 50 of the order of 0.01 to 10 ⁇ M.
  • the compounds of the invention can be used for the treatment of behavioral disorders associated with dementia, psychoses, in particular schizophrenia (deficit form and productive form) and acute or chronic extrapyramidal symptoms induced by neuroleptics.
  • schizophrenia deficit form and productive form
  • extrapyramidal symptoms induced by neuroleptics for the treatment of various forms of anxiety, panic attacks, phobias, obsessive compulsive disorder
  • for the treatment of various forms of depression, including psychotic depression for the treatment of disorders due to abuse or withdrawal alcohol, sexual behavior disorders, eating disorders, and for the treatment of migraine.
  • the compounds of the invention can be used for the treatment of painful muscular contractures in rheumatology and in acute spinal pathology, for the treatment of spastic contractures of medullary or cerebral origin, for the symptomatic treatment of acute and subacute pain.
  • mild to moderate intensity for the treatment of intense and / or chronic pain, neurogenic pain and rebellious pain, for the treatment of Parkinson's disease and parkinsonian symptoms of neurodegenerative origin or induced by neuroleptics
  • the present invention also relates to pharmaceutical compositions containing an effective dose of at least one compound according to the invention, in the base state or of a pharmaceutically acceptable salt or solvate, and as a mixture, as the case may be. if necessary, with suitable excipients. Said excipients are chosen according to the pharmaceutical form and the desired mode of administration.
  • the pharmaceutical compositions according to the invention can thus be intended for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, intratracheal, intranasal, transdermal, rectal, intraoccular administration.
  • the unit administration forms can be, for example, tablets, capsules, granules, powders, oral or injectable solutions or suspensions, transdermal patches ("patch"), suppositories.
  • patch transdermal patches
  • ointments ointments, lotions and eye drops can be considered.
  • Said unit forms are dosed to allow daily administration of 0.01 to 20 mg of active principle per kg of body weight, depending on the dosage form.
  • a pharmaceutical carrier is added to the active principle, micronized or not, which can be composed of diluents, such as, for example, lactose, microcrystalline cellulose, starch, and formulation adjuvants such as binders, (polyvinylpyrrolidone, hydroxypropylmethylcellulose, etc.), flow agents such as silica, lubricants such as magnesium stearate, stearic acid, glycerol tribehenate, sodium stearyl fumarate. Wetting agents or surfactants such as sodium lauryl sulfate can also be added.
  • the production techniques can be direct compression, dry granulation, wet granulation or hot melting.
  • the tablets can be plain, coated, for example with sucrose, or coated with various polymers or other suitable materials. They can be designed to allow rapid, delayed or prolonged release of the active ingredient using polymer matrices or polymers specific used in the coating.
  • the active ingredient is mixed with dry pharmaceutical vehicles (simple mixing, dry or wet granulation, or hot fusion), liquids or semi-solids.
  • the capsules can be hard or soft, film-coated or not, so as to have rapid, prolonged or delayed activity (for example for an enteric form).
  • a composition in the form of a syrup or elixir or for administration in the form of drops may contain the active principle together with a sweetener, preferably calorie-free, methylparaben or propylparaben as an antiseptic, a flavoring agent and a coloring agent.
  • a sweetener preferably calorie-free, methylparaben or propylparaben as an antiseptic, a flavoring agent and a coloring agent.
  • the powders and granules dispersible in water can contain the active principle in mixture with dispersing agents or wetting agents, or dispersing agents such as polyvinylpyrrolidone, as well as with sweeteners and flavor correcting agents.
  • aqueous suspensions For parenteral administration, aqueous suspensions, isotonic saline solutions or sterile injectable solutions containing pharmacologically compatible dispersing agents and / or wetting agents, for example propylene glycol or butylene glycol, are used.
  • pharmacologically compatible dispersing agents and / or wetting agents for example propylene glycol or butylene glycol
  • the active principle can also be formulated in the form of microcapsules, optionally with one or more carriers or additives, or with a polymer matrix or with a cyclodextrin (transdermal patches, extended release forms).
  • compositions according to the invention comprise a medium compatible with the skin. They may be in particular in the form of aqueous, alcoholic or hydroalcoholic solutions, gels, water-in-oil or oil-in-water emulsions having the appearance of a cream or gel, microemulsions, d aerosols, or in the form of vesicular dispersions containing ionic and / or nonionic lipids. These dosage forms are prepared according to the usual methods of the fields considered.
  • compositions according to the invention may contain, alongside a compound of general formula (I), other active ingredients which may be useful in the treatment of the disorders and diseases indicated above.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP04791551A 2003-10-17 2004-10-15 Derives de n-[[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique Withdrawn EP1680402A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0312140A FR2861074B1 (fr) 2003-10-17 2003-10-17 Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
PCT/FR2004/002640 WO2005037792A1 (fr) 2003-10-17 2004-10-15 Derives de n-``phenyl(piperidin-2-yl)methyl !benzamide, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
EP1680402A1 true EP1680402A1 (fr) 2006-07-19

Family

ID=34385233

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04791551A Withdrawn EP1680402A1 (fr) 2003-10-17 2004-10-15 Derives de n-[[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique

Country Status (18)

Country Link
US (2) US7750025B2 (enrdf_load_stackoverflow)
EP (1) EP1680402A1 (enrdf_load_stackoverflow)
JP (1) JP2007508358A (enrdf_load_stackoverflow)
KR (1) KR20060094079A (enrdf_load_stackoverflow)
CN (1) CN1882540A (enrdf_load_stackoverflow)
AU (1) AU2004281214B2 (enrdf_load_stackoverflow)
BR (1) BRPI0415504A (enrdf_load_stackoverflow)
CA (1) CA2542373A1 (enrdf_load_stackoverflow)
FR (1) FR2861074B1 (enrdf_load_stackoverflow)
IL (1) IL174942A (enrdf_load_stackoverflow)
MA (1) MA28101A1 (enrdf_load_stackoverflow)
ME (1) MEP12508A (enrdf_load_stackoverflow)
NO (1) NO20062105L (enrdf_load_stackoverflow)
NZ (1) NZ547164A (enrdf_load_stackoverflow)
RS (1) RS20060318A (enrdf_load_stackoverflow)
RU (1) RU2351588C2 (enrdf_load_stackoverflow)
WO (1) WO2005037792A1 (enrdf_load_stackoverflow)
ZA (1) ZA200603937B (enrdf_load_stackoverflow)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2842804B1 (fr) 2002-07-29 2004-09-03 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
GB0600427D0 (en) * 2006-01-10 2006-02-15 Glaxo Group Ltd Compounds
JP2010523476A (ja) 2007-03-08 2010-07-15 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ ミトコンドリアアルデヒドデヒドロゲナーゼ−２モジュレーター及びその使用方法
FR2917735B1 (fr) * 2007-06-21 2009-09-04 Sanofi Aventis Sa Nouveaux indazoles substitutes, leur preparation et leur utilisation en therapeutique
WO2009013535A1 (en) * 2007-07-23 2009-01-29 Astrazeneca Ab 2-azabicyclo(2.2.2)octane derivatives as modulators of the glycine transporter i receptor
CA2691450A1 (en) 2007-08-22 2009-02-26 Abbott Gmbh & Co. Kg 4-benzylaminoquinolines, pharmaceutical compositions containing them, and their use in therapy
ES2397764T3 (es) 2008-04-01 2013-03-11 Abbott Gmbh & Co. Kg Tetrahidroisoquinolinas, composiciones farmacéuticas que las contienen, y su uso en terapia
JP2012502048A (ja) 2008-09-08 2012-01-26 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼ活性のモジュレーターおよびその使用方法
KR20110082180A (ko) * 2008-10-28 2011-07-18 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 알데히드 탈수소효소의 조절자 및 그것의 사용방법
PE20120500A1 (es) * 2009-01-27 2012-05-04 Hoffmann La Roche Piperidinas sustituidas con heteroilamino y aroilamino como inhibidores de glyt-1
AR075182A1 (es) * 2009-01-28 2011-03-16 Astrazeneca Ab Compuestos 2-aza-biciclo (2.2.2) octano y sus usos
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
MX2011009677A (es) * 2009-03-16 2011-09-30 Sanofi Sa Derivados de n-[(2-aza-biciclo[2.1.1]hex-1-il)-aril-metil]-heterob enzamida, su preparacion y su aplicacion en terapeutica.
FR2943056A1 (fr) * 2009-03-16 2010-09-17 Sanofi Aventis Derives de n-°2-aza-bicyclo°2.1.1!hex-1-yl)-aryl-methyl!- heterobenzamide, leur preparation et leur application en therapeutique
FR2944283B1 (fr) * 2009-04-14 2011-05-06 Sanofi Aventis Derives de n-°(2-aza-bicyclo°2.1.1!hex-1-yl)-aryl-methyl!- heterobenzamide, leur preparation et leur application en therapeutique
JP5618047B2 (ja) * 2010-01-29 2014-11-05 国立大学法人千葉大学 ポジトロン断層撮影法およびポジトロン放出化合物
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
MX2014001457A (es) 2011-08-05 2014-08-21 Abbvie Deutschland Derivados de aminocromano, de aminotiocromano y de amino-1,2,3,4-tetrahidroquinolina composiciones farmaceuticas que los contienen, y su uso en terapia.
MX2014006004A (es) 2011-11-18 2015-04-16 Abbvie Deutschland Derivados de aminobenzociclohepteno, aminotetralina, aminoindano y fenalcilamina n-sustituidas, composiciones farmaceuticas que los contienen, y su uso en terapia.
FR2983197B1 (fr) * 2011-11-29 2014-07-25 Assist Publ Hopitaux De Paris Utilisation de phacetoperane pour traiter un trouble deficit de l'attention hyperactivite
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
CN105358531B (zh) 2013-03-14 2017-11-14 利兰-斯坦福大学初级学院的董事会 线粒体醛脱氢酶‑2调节剂和其使用方法
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
JP2016533375A (ja) 2013-10-17 2016-10-27 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー アミノテトラリン誘導体およびアミノインダン誘導体、これらを含有する医薬組成物、および治療におけるこれらの使用
CN105992764A (zh) 2013-10-17 2016-10-05 艾伯维德国有限责任两合公司 氨基色满、氨基硫代色满及氨基-1,2,3,4-四氢喹啉衍生物，包含其的药物组合物及其在治疗中的用途
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
RU2680526C1 (ru) * 2016-07-05 2019-02-22 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Нейропротекторное средство, обладающее свойствами антиоксиданта и донатора оксида азота
US11203582B2 (en) 2017-06-15 2021-12-21 The Board Of Regents Of The University Of Oklahoma Benzamide derivatives for inhibiting endoplasmic reticulum (ER) stress

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2928835A (en) 1959-02-19 1960-03-15 Rhone Poulenc Sa New esters
US3336300A (en) 1965-04-13 1967-08-15 American Home Prod 1, 2, 3, 4-tetrahydro-5h-benzodiazepin-5-ones
JPH02262562A (ja) 1988-10-20 1990-10-25 Ishihara Sangyo Kaisha Ltd イミダゾール系化合物
JP2765876B2 (ja) 1988-10-24 1998-06-18 科研製薬株式会社 ピリジルケトオキシムエーテル誘導体
US5254569A (en) * 1991-01-14 1993-10-19 The Du Pont Merck Pharmaceutical Company (Amidomethyl)nitrogen heterocyclic analgesics
JP3026845B2 (ja) * 1991-02-20 2000-03-27 日清製粉株式会社 ピペリジン誘導体
SE9400447D0 (sv) * 1994-02-11 1994-02-11 Astra Ab New compounds
FR2838739B1 (fr) * 2002-04-19 2004-05-28 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl)benzamide, leur preparation et leur application en therapeutique
FR2842804B1 (fr) * 2002-07-29 2004-09-03 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861073B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861071B1 (fr) 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[phenyl(alkylpiperidin-2-yl) methyl]benzamide, leur prepartation et leur application en therapeutique
FR2861070B1 (fr) 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[phenyl(pyrrolidin-2-yl)methyl]benzamide et n-[(azepan-2-yl)phenylmethyl]benzamide, leur preparation et leur application en therapeutique
FR2861076B1 (fr) 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-heterocyclymethylbenzamide, leur preparation et leur application en therapeutique
FR2906251B1 (fr) * 2006-09-22 2008-11-07 Sanofi Aventis Sa Derives de pyrrolizine, indolizine et quinolizine, leur preparation et leur application en therapeutique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005037792A1 *

Also Published As

Publication number Publication date
CN1882540A (zh) 2006-12-20
US20100234424A1 (en) 2010-09-16
CA2542373A1 (fr) 2005-04-28
MA28101A1 (fr) 2006-08-01
BRPI0415504A (pt) 2006-12-12
US7750025B2 (en) 2010-07-06
IL174942A (en) 2011-03-31
NO20062105L (no) 2006-05-10
FR2861074A1 (fr) 2005-04-22
RU2006116885A (ru) 2007-11-27
ZA200603937B (en) 2009-01-28
WO2005037792A1 (fr) 2005-04-28
FR2861074B1 (fr) 2006-04-07
KR20060094079A (ko) 2006-08-28
AU2004281214B2 (en) 2010-07-08
IL174942A0 (en) 2006-08-20
RU2351588C2 (ru) 2009-04-10
RS20060318A (en) 2008-11-28
JP2007508358A (ja) 2007-04-05
NZ547164A (en) 2009-11-27
MEP12508A (en) 2010-06-10
US20060223885A1 (en) 2006-10-05
AU2004281214A1 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
EP1680402A1 (fr) Derives de n-[[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
EP1499589B1 (fr) Derives de n-¬phenyl(piperidin-2-yl)methyl|benzamide, leur preparation et leur application en therapeutique
EP1527048B1 (fr) Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
EP1680418B1 (fr) Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
EP1680400B1 (fr) Derives de n-[ phenyl(pyrrolidin-2-yl)methyl]benzamide, et n-[(azepan-2-yl) phenylmethyl]benzamide, leur preparation et leur application en therapeutique
EP1682503B1 (fr) Derives de n-[phenyl(alkylpiperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
WO2004013100A2 (fr) Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
EP2077837A2 (fr) Derives de pyrrolizine, indolizine et quinolizine, leur preparation et leur application en therapeutique.
EP0520882B1 (fr) Dérivés de 2-aminopyrimidine-4-carboxamide, leur préparation et leur application en thérapeutique
EP0522914A1 (fr) Dérivés de 2-pipéridinylpyrimidine-4-carboxamide, leur préparation et leur application en thérapeutique
CA2758367A1 (fr) Derives de n-[(7-aza-bicyclo[2.2.1]hept-1-yl)-aryl-methyl]-benzamide, leur preparation et leur application en therapeutique
HK1098143A (en) Derivatives of n-"phenyl(piperidine-2-yl) methyl benzamide, preparation method thereof and applications of same in therapeutics
HK1038927B (en) (1-phenacy-3-phenyl-3-piperidylethyl) piperidine derivatives, method for the production thereof and pharmaceutical compositions containing the same
HK1038927A1 (en) (1-Phenacy-3-phenyl-3-piperidylethyl) piperidine derivatives, method for the production thereof and pharmaceutical compositions containing the same
MXPA06004268A (en) Derivatives of n-``phenyl(piperidine-2-yl) methyl benzamide, preparation method thereof and applications of same in therapeutics
EP2396334A1 (fr) Derives de n-[(2-aza-bicyclo[2.1.1]hex-1-yl]-aryl-methyl]-benzamide, leur preparation et leur application en therapeutique
EP2396335A1 (fr) Derives de n-[(6-aza-bicyclo[3.2.1]oct-1-yl)-aryl-methyl]-benzamide, leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060517

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

17Q First examination report despatched

Effective date: 20090126

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SANOFI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SANOFI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SANOFI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120411